340B Program: Policy Overhaul Coming in 2026?

The 340B program, established in 1992, aimed to help safety-net healthcare providers stretch their federal resources further by enabling them to purchase outpatient drugs at significantly discounted prices. This seemingly straightforward initiative, designed to lower drug costs for vulnerable populations, has instead become a lightning rod for controversy, with its unintended effects now reshaping healthcare policy and raising fundamental questions about its future. Is the program truly benefiting those it was intended to serve, or has it become a complex financial engine with disparate impacts?

The Unintended Expansion of 340B

When Congress enacted Section 340B of the Public Health Service Act, the goal was clear: provide discounted drugs to hospitals and clinics serving a disproportionate share of uninsured and low-income patients. The idea was that these savings would then be reinvested into patient care, in the end benefiting those in need. What transpired, however, was an expansion far beyond its initial scope, particularly with the proliferation of contract pharmacy arrangements.

Today, the program encompasses a vast network of hospitals, federally qualified health centers, and other entities, many of which now operate hundreds of contract pharmacies. This growth has fueled accusations from pharmaceutical manufacturers and some policymakers that the program has strayed from its safety-net mission, becoming a revenue generator for hospitals and a source of profit for pharmacy benefit managers (PBMs). A 2023 report from the Government Accountability Office (GAO) found that while 340B discounts are substantial, there’s limited oversight to ensure these savings directly translate into lower drug prices for patients or enhanced services for the uninsured. This is a critical point. The program’s design allows covered entities considerable flexibility in how they use the savings, which, while intended to support diverse patient needs, also creates a significant transparency gap.

The sheer volume of discounted drugs moving through the 340B program is staggering. According to data from the Health Resources and Services Administration (HRSA), the program’s administrator, the total value of 340B drug purchases continues to climb annually, reaching tens of billions of dollars. This financial scale shows the program’s impact on the entire pharmaceutical supply chain and explains why debates around its structure are so fervent. It’s not just about a small discount anymore. It’s a massive market force.

Manufacturers’ Pushback and Contract Pharmacy Disputes

The rapid growth of the 340B program, particularly through contract pharmacies, has not gone unchallenged. Pharmaceutical manufacturers argue that the expansion has led to significant financial losses for them, forcing them to offer deep discounts on drugs that are often dispensed to commercially insured patients, not just the uninsured. This sentiment has led to a series of actions by manufacturers to limit 340B discounts, primarily by restricting access to these discounts for drugs dispensed through contract pharmacies.

Starting in 2020, several major pharmaceutical companies, including Eli Lilly, AstraZeneca, and Sanofi, began implementing policies to limit 340B drug shipments to contract pharmacies, often requiring covered entities to designate a single contract pharmacy or to provide patient-level data. These actions ignited a firestorm of legal battles. Covered entities, supported by HRSA, argued that manufacturers were violating federal law by refusing to provide mandatory 340B discounts. Conversely, manufacturers contended that the original intent of the program did not envision the widespread use of contract pharmacies for commercially insured patients and that they were simply trying to prevent diversion and ensure program integrity.

The legal field surrounding these disputes remains complex and evolving. Federal courts have issued conflicting rulings, with some siding with HRSA and covered entities, and others providing a degree of latitude to manufacturers. For instance, a decision in the Third Circuit Court of Appeals in 2023, while not fully resolving the issue, acknowledged some of the manufacturers’ concerns regarding the scope of the program. This ongoing legal uncertainty creates significant operational challenges for covered entities and manufacturers alike, disrupting drug access and increasing administrative burdens. My professional assessment is that without clearer legislative guidance, these skirmishes will continue, creating instability in drug pricing and supply chains.

Impact on Drug Pricing and Patient Access

The core promise of the 340B program is to lower drug costs for vulnerable patients. However, the actual impact on patient-level drug pricing is often opaque. While covered entities receive substantial discounts, there is no federal mandate requiring them to pass these savings directly to patients, especially those with insurance. Many hospitals use the savings to subsidize other services, fund charity care, or expand facilities. While these are laudable goals, they don’t always translate into a direct reduction in out-of-pocket costs at the pharmacy counter for individual patients.

For uninsured patients, the program theoretically offers a lifeline. However, access to 340B priced drugs can be inconsistent. A patient might receive a discounted drug at a hospital’s in-house pharmacy, but if they use a contract pharmacy that doesn’t have a direct arrangement to pass on the full discount, or if the hospital’s policy doesn’t explicitly require it, the savings may not materialize. This variability creates a postcode lottery for drug affordability, where access to discounted medication depends heavily on where a patient seeks care and the specific policies of that particular covered entity.

Plus, the manufacturer restrictions on contract pharmacies have directly impacted patient access in some instances. When manufacturers limit shipments to specific pharmacies, patients who rely on a different contract pharmacy for convenience or necessity may find it harder to obtain their medications. This is particularly problematic in rural areas where options are already limited. For example, a patient in rural Georgia might rely on a specific local pharmacy that previously served as a contract pharmacy for a nearby critical access hospital. If that arrangement is disrupted due to manufacturer policies, the patient might face significant travel burdens or be forced to pay higher prices for their prescriptions.

Policy Discussions and Potential Reforms in 2026

The complexities and controversies surrounding the 340B program have made it a recurring topic in Washington. In 2026, discussions are intensifying around potential reforms aimed at increasing transparency and ensuring the program better aligns with its original intent. One of the most frequently proposed solutions is enhanced data reporting requirements for covered entities. The argument is simple: if hospitals and clinics are receiving substantial discounts, they should be able to demonstrate how those savings are being used to benefit patients.

Lawmakers are exploring several avenues, including requiring covered entities to report annually on how 340B savings are reinvested, including the amount of uncompensated care provided, charity care, and specific programs funded. There’s also a strong push to clarify the definition of an “eligible patient” under the program. Currently, some critics argue that the definition is too broad, allowing commercially insured patients who could otherwise afford their medications to benefit from the discounts, thus diluting the program’s impact on truly vulnerable populations.

Another area of intense focus is the regulation of contract pharmacies. Some legislative proposals suggest establishing clearer guidelines for these arrangements, potentially limiting the number of contract pharmacies a covered entity can use or imposing stricter requirements on how discounts are passed through. The goal here is to strike a balance: preserve the ability of covered entities to expand access to discounted drugs while preventing perceived abuses or unintended profits. My view is that any meaningful reform will need to address the contract pharmacy issue head-on, as it’s the primary driver of much of the current contention.

The political will for complete reform remains to be seen. Any changes to 340B will face significant opposition from various stakeholders, including hospital associations, patient advocacy groups, and some pharmacy organizations, all of whom benefit from the program’s current structure. However, the growing consensus that the program needs greater accountability suggests that some form of legislative action is likely in the coming years. The challenge will be to enact reforms that truly address the unintended consequences without undermining the program’s legitimate role in supporting safety-net providers.

The 340B program’s journey from a targeted initiative to a sprawling, complex system illustrates the challenges of healthcare policy. Its unintended effects, from manufacturer pushback to debates over patient benefits, highlight the need for careful re-evaluation. Moving forward, policymakers must prioritize transparency and accountability to ensure that the program genuinely serves its foundational purpose of reducing drug prices for those who need it most.